Literature DB >> 1247522

Characterization of human, bovine, and horse antithrombin III.

K Kurachi, G Schmer, M A Hermodson, D C Teller, E W Davie.   

Abstract

A comparison of the physical-chemical properties of human, bovine, and horse antithrombin III has been made. These three plasma proteins are strong inhibitors of bovine factor Xa and form a 1:1 molar complex with this coagulation enzyme. Human, bovine, and horse antithrombin III are glycoproteins containing hexose, hexosamine, and neuraminic acid. The total carbohydrate was 9, 12, and 16% for human, bovine, and horse antithrombin III, respectively. These proteins have a similar amino acid composition, although some monor variations were noted. Each antithrombin III is composed of a single polypeptide chain with an amino-terminal histidine residue. Of the first 17 amino-terminal residues, only three differences were noted between the three proteins. These occur in position 2 which is occupied by Gly, Arg, and Trp in human, bovine, and horse, respectively; position 6 which has a deletion in human antithrombin III; and position 8 where Ile in human and horse antithrombin III has been replaced by Val in the bovine preparation. The remainder of the first 17 residues is the same in all three proteins. The molecular weights for the bovine and horse preparation were 56 600 and 52 500, respectively, as determined by sedimentation equilibrium in the presence of guanidine hydrochloride. Some immunological cross-reactivity was also observed between the three different proteins.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1247522     DOI: 10.1021/bi00647a020

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  18 in total

1.  Inhibition of activated protein C by platelets.

Authors:  S M Jane; C A Mitchell; L Hau; H H Salem
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

2.  The equine protease inhibitory system (Pi): abnormal expressions of PiF, PiL, and PiS1.

Authors:  S D Patterson; K Bell
Journal:  Biochem Genet       Date:  1986-08       Impact factor: 1.890

3.  Clearance of thrombin from circulation in rabbits by high-affinity binding sites on endothelium. Possible role in the inactivation of thrombin by antithrombin III.

Authors:  P Lollar; W G Owen
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

Review 4.  Mechanism of the anticoagulant action of heparin.

Authors:  I Björk; U Lindahl
Journal:  Mol Cell Biochem       Date:  1982-10-29       Impact factor: 3.396

5.  Comparison of the behaviour in vivo of two molecular forms of antithrombin III.

Authors:  T H Carlson; A C Atencio; T L Simon
Journal:  Biochem J       Date:  1985-02-01       Impact factor: 3.857

6.  Activation of human factor IX (Christmas factor).

Authors:  R G Di Scipio; K Kurachi; E W Davie
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

7.  Cloning and expression of the cDNA for human antithrombin III.

Authors:  S C Bock; K L Wion; G A Vehar; R M Lawn
Journal:  Nucleic Acids Res       Date:  1982-12-20       Impact factor: 16.971

8.  The complete amino acid sequence of bovine antithrombin (ATIII).

Authors:  H Mejdoub; M Le Ret; Y Boulanger; M Maman; J Choay; J Reinbolt
Journal:  J Protein Chem       Date:  1991-04

9.  Detection of a new heparin-dependent inhibitor of thrombin in human plasma.

Authors:  D M Tollefsen; M K Blank
Journal:  J Clin Invest       Date:  1981-09       Impact factor: 14.808

10.  The activation of the alternative pathway C3 convertase by human plasma kallikrein.

Authors:  R G DiScipio
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.